|
|
Vaccine Detail
|
12MP, 12MP/Tet, 12MP/6MHP, or 6MHP |
| Vaccine Information |
- Vaccine Name: 12MP, 12MP/Tet, 12MP/6MHP, or 6MHP
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007190
- Type: multipeptide
- Status: Clinical trial
- Immunization Route: Intramuscular injection (i.m.)
- Description: 4 treatment groups, vaccinated with 12 MHC class I-restricted melanoma peptides to stimulate CTL (12 MP, group A), plus a tetanus peptide (group B), or a mixture of 6 melanoma helper peptides (6 MHP, group C) to stimulate helper T lymphocytes (HTL), or with 6 melanoma helper peptide (6 MHP) alone (group D), in incomplete Freund's adjuvant plus granulocyte macrophage colony-stimulating factor (Slingluff et al., 2013), https://pubmed.ncbi.nlm.nih.gov/23653149/
|
| Host Response |
|
|
| References |
Slingluff et al., 2013: Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(15); 4228-4238. [PubMed: 23653149].
|
|
